A $4.6bn Wipeout And China Pharma Accounting's Wild West
Tougher New Rules Follow Kangmei Debacle
Executive Summary
A drug maker’s downfall prompts a new wave of regulatory crackdowns on accounting and audit fraud in China with broad implications across industry sectors.